Therapy Areas: Vaccines
4basebio secures clinical supply agreement for Phase II immunotherapy trial
20 May 2026 - Cambridge-based biotechnology company 4basebio PLC (AIM: 4BB) disclosed on Wednesday that it has signed a Clinical Supply Agreement with an unnamed cancer immunotherapy developer to prov...
GSK's Arexvy gains expanded approval in Japan for at-risk adults aged 18-49
18 May 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) disclosed on Monday that Japan's Ministry of Health, Labour and Welfare has expanded approval for its RSV vaccine, Arexvy, t...
Bavarian Nordic secures USD97m US vaccine contract expansion and raises 2026 outlook
12 May 2026 - Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced late Monday that the US Biomedical Advanced Research and Development Authority (BARDA) has exercised contract opti...
Anixa Biosciences reports extended survival signals in Phase 1 ovarian cancer CAR-T trial
11 May 2026 - Biotechnology company Anixa Biosciences Inc (NASDAQ: ANIX) on Monday reported updated positive survival observations from its ongoing Phase 1 trial of liraltagene autoleucel (lira-cel), ...
4basebio introduces enzymatic ssDNA platform for gene editing applications
11 May 2026 - Cambridge-based biotechnology company 4basebio PLC (AIM: 4BB) announced on Monday that it has launched a high-capacity single-stranded DNA (ssDNA) platform designed to support the develo...
WuXi Biologics announces structural completion and key equipment arrival at Chengdu microbial manufacturing site
27 April 2026 - WuXi Biologics (HK:2269), a China-based, global Contract Research, Development and Manufacturing Organisation (CRDMO), announced on Friday the structural completion and key equipment a...